A recent longitudinal study concluded that older adults with impaired odor identification were more likely to develop dementia than those with intact odor identification after controlling for other sociodemographic and healthrelated factors. 1 The authors suggest that this is the first longitudinal study with such a result and argue that odor testing is "an opportunity for early interventions to reduce the attendant morbidity and public health burden of dementia."
Although this research indirectly advances the science of dementia, considerable caution is required before drawing any conclusions about how olfactory testing could or should be applied in clinical or public health settings. In particular, it is essential to consider the relationship between the predictor and the outcome, the positive predictive value (PPV) and negative predictive value (NPV) of the test, the personal consequences of making a presumptive dementia diagnosis, the systematic scrutiny of screening tests, and the role of screening in person-centered care. On all these fronts, scrutiny of the findings argues against changing any practice related to the identification of dementia.
AN EARLY SYMPTOM IS NOT A RISK FACTOR
Although this study found that olfactory dysfunction may precede dementia, by no means could it be considered a factor that causes or increases the likelihood of dementia. Olfactory dysfunction is not something to which an individual is exposed, nor is it a sociodemographic or healthrelated characteristic of an individual. The only plausible way to associate it with dementia is to define it as an early sign of the disease, present before other cognitive impairments appear. Older research, some of which the researchers cite, has shown that many individuals with dementia have an impaired sense of smell, but it is unclear why the disease sometimes manifests with this symptom. Olfactory dysfunction should thus be seen as a finding that may occur early in dementia in some cases. It might fairly be described as an "epiphenomenon."
In this light, olfactory dysfunction would be most useful for advancing the science of dementia if its epidemiology, pathophysiology, and natural history could be correlated with that of dementia. The authors speculate that olfactory testing could differentiate between dementia subtypes (e.g., frontotemporal, vascular). Unfortunately, the causes of olfactory dysfunction are as nebulous as the causes of dementia, and additional research is needed to elucidate them. For instance, there might be associations between olfactory dysfunction and head injury, microvascular pathology, genetic factors, other neuropsychiatric diseases, or environmental exposures. Olfactory dysfunction may be easier to quantify across time than global cognition, which could allow for more-systematic or earlier assessment of neurodegenerative changes, but none of this supports that smell testing would be a useful tool for predicting the onset of dementia.
THE CRITICAL RESULTS ARE THE PREDICTIVE VALUES
The study found that olfactory dysfunction had 47% sensitivity and 79% specificity in predicting dementia 5 years later. Given the population prevalence, this corresponds with a 9% PPV and a 97% NPV. To make this explicit, one of 11 of those who received a positive test result developed dementia, and 29 of 30 of those who received a negative result did not develop dementia. For a clinical test, or for any meaningful measure of association, these results are poor, regardless of the level of statistical significance.
Insofar as the critical clinical and public health issue is early identification of dementia cases, the most important result is PPV, which was 9%. On a population level, this would correspond to a large number of false-positive results-people who are told that they are at high likelihood of developing dementia who are not actually at risk.
No test with such a low PPV would be taken seriously as a way to identify any disease in a population. It is essential to consider the consequences of false positive results for individuals and healthcare systems. The only meaningful result would be a negative test, which could plausibly reassure older adults that they are unlikely to develop dementia. Unfortunately, screening tests cannot selectively be applied to individuals on the basis of their risk, as a way to "confirm exclusion." Using an olfactory screen would necessarily generate false positive results.
would probably not be able to identify causes other than dementia of your trouble with identifying smells, leaving dementia as the only remaining cause. You would be leftfollowing the authors' logic-with the assumption that you were at high risk of having the disease within 5 years. You would likely be distressed if you noticed any lapses in memory or cognition, however benign. There are no curative treatments for dementia, so you would assume that you would develop, suffer through, and possibly die of an often devastating process that involves loss of role functioning, identify, and self-care. You would expect to be a burden on your family and to expend your savings on care. You would have to decide what to tell family members and friends, because it is likely that sharing such information would spread the distress. You might forgo making long-term plans, assuming that you were at the start of a downward decline. All this would, most likely, be entirely unnecessary worry and suffering, because the chances are minimal (9%) that you would actually develop dementia. Screening carries real risks if the condition is serious and cannot be treated, especially if the positive result is materially wrong. A wrong diagnosis can produce real human suffering for individuals and their loved ones.
SYSTEMATIC APPROACHES TO DEMENTIA SCREENING RECOMMEND AGAINST IT
The U.S. Preventative Services Task Force (USPSTF) found insufficient evidence to recommend screening for cognitive impairment, 2 the Veterans Affairs National Center for Health Promotion and Disease Prevention does not recommend screening, 3 and the Canadian Task Force on Preventive Health Care has recommended against screening asymptomatic adults. 4 These conclusions were grounded in considerations like those discussed just above (sensitivity, specificity, and predictive value of tests; consequences of various test outcomes; availability of treatments; effects on clinical care). The researchers acknowledge the recommendations of the USPSTF, and they should subject their results to the scrutiny of such a review body before recommending, as the result of a single study, that olfactory testing possesses merit for screening. Given the extremely poor PPV of olfactory testing, it seems unlikely that any of these agencies would change its recommendations about screening after evaluating it.
The USPSTF's and other guidelines are focused on asymptomatic individuals, and it is possible that, if older adults present with concerns about cognitive impairment, or their families notice them, or if there were dementia warning signs, olfactory screening would have a higher PPV and NPV and thus more clinical utility. The current study cannot answer that question, because the study population was part of a panel survey of older Americans. Additional research could be performed in memory disorder clinics, where almost all individuals present because of concerns and not as a result of screening.
DISCUSS OLFACTORY TESTING INSTEAD OF, OR AT LEAST BEFORE, PERFORMING IT
Despite these fundamental problems with the application and consequences of olfactory testing, the authors are optimistic about its utility, and some clinicians might, given the relative simplicity and low cost of the test, be inclined to use it. It is essential, in the interests of keeping medical care focused on the individual, that the properties of the test be discussed before administering it and the individual be given a choice of undergoing this test. It is easy to describe PPV and NPV, especially using graphics (such as 10 9 10 matrices of hypothetical individuals, with coding depending on outcomes, such as different colors for true positive, true negative, false positive, and false negative). The most important fact to communicate is that, "If you receive a positive test, you will have a 9% chance of having dementia in five years." The second is, "If you receive a negative test, you will have a 97% chance of not having dementia in five years." Based on their values and preferences and their comfort with uncertainty, different people will make different decisions about whether or when to undergo olfactory testing. The decision is the individual's, not the provider's.
It would be a grave disservice to patients and contrary to principles of person-centered care and possibly to the goal of "doing no harm" to order testing without ensuring that the patient fully understands the test and how it could be interpreted. No provider wishes for false-positive results, but given the test properties, such results will happen frequently. Subjecting an individual to the expectation of future dementia when the probability is less than 10% can only be interpreted as a harm.
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